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 Introduction 
 Matrix metalloproteinases (MMPs) and their tissue 
inhibitors (TIMPs) participate in extracellular matrix 
(ECM) tissue remodeling in both normal and pathologi-
cal conditions  [1–3] . TIMPs form non-covalent bimolec-
ular 1:  1 complexes with MMP pro-forms; therefore ratios 
between MMPs and TIMPs reflect to a certain extent the 
overall proteolytic activity. An increase in active MMPs 
may indicate a disparity between TIMPs and pro-MMPs 
 [1–3] . The constitutively expressed matrix metallopro-
teinases type 2 (MMP-2) and type 9 (MMP-9) seem to be 
involved in mechanisms of T-cell migration into the pe-
ripheral nerve and skeletal muscle  [2, 4–7] . Inflamma-
tory myopathies such as polymyositis (PM) and sporadic 
inclusion body myositis (sIBM) show a strong upregula-
tion of MMP-9 and to a less significant extent of MMP-2 
at atrophic and inflamed myofibers  [2, 4, 6, 7] . In walle-
rian degeneration and regeneration of peripheral nerves, 
macrophages and other epi- and endoneural cells, in-
volved in nerve repair in vivo, secrete e.g. MMP-2 and 
MMP-9  [5, 8] . 
 Chronic severe immune-mediated neuromuscular 
disorders like chronic inflammatory demyelinating neu-
ropathy (CIDP), multifocal motor neuropathy (MMN) 
and inflammatory myopathies are treated with intrave-
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 Abstract 
 We monitored serum levels of matrix metalloproteinases 
(MMPs) and their tissue inhibitors (TIMPs) before and during 
intravenously applied immunoglobulin (IVIG) therapy in 33 
patients with chronic immune-mediated neuropathies and 
myopathies and 15 controls. Baseline MMP-2 and TIMP-2 se-
rum levels were lower and MMP-9 and TIMP-1 serum levels 
higher in all patients compared to age-matched controls. 
Eight days after IVIG treatment, MMP-2, TIMP-2, and TIMP-1 
serum levels increased, while MMP-9 serum levels decreased, 
indicating tissue repair. After 60 days, MMP-9 levels in-
creased, MMP-2 approached normal levels, while TIMP-1 and 
TIMP-2 serum levels were below day 8 levels, indicating re-
lapsing tissue damage. Comparing the MMP/TIMP results 
with the clinical courses, IVIG treatment tended to change 
MMP/TIMP levels in a way that paralleled clinical improve-
ment and relapse. In sum, during a distinct time period, IVIG 
therapy seems to be able to modulate MMP-mediated tissue 
repair.  Copyright © 2006 S. Karger AG, Basel 
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nously administered immunoglobulins (IVIG) [for re-
views, see  9, 10] . Apart from clinical and electrophysio-
logical follow-up parameters, the correlation of disease 
activity to specific antibodies or immune-mediated se-
rum protein levels is often uncertain. 
 The aim of this pilot study was to investigate effects
of high-dose IVIG on serum levels of MMP-2, MMP-9, 
 tissue inhibitor of metalloproteinases type 1 (TIMP-1), 
type 2 (TIMP-2) and their ratios. A change in ratio was 
supposed to be helpful detecting treatment-related effects 
in patients with PM, sIBM, CIDP, and MMN.
Patients and Methods 
 Fifteen patients with electron microscopically-proven sIBM 
(5 women and 10 men, mean age 68.4 years, range 59–82 years, 
mean disease duration 5.1 years), 4 patients with biopsy-proven 
PM (3 women and 1 man, mean age 58 years, range 46–73 years, 
mean disease duration 3.6 years), 11 patients with electrophysio-
logically-proven MMN (4 women and 7 men, mean age 57.7 years, 
range 48–71 years, mean disease duration 2.8 years), and 3 pa-
tients with clinical, cerebrospinal fluid and electrophysiological 
signs of CIDP (1 woman and 2 men, mean age 58 years, range 
40–72 years, mean disease duration 4.2 years) were prospectively 
investigated. A sequential electrophysiological analysis (days 0 
and 60) was performed in all patients, but did not show any sig-
nificant differences in the chosen follow-up period (data not 
shown). Clinical follow-up was monitored by neuromuscular 
scores (Medical Research Council (MRC) scale, Neuromuscular 
Symptoms Score (NSS, 18) and the Angelini score at admission 
and on days 8, 30 and 60. Patients with sIBM, MMN and CIDP 
did not receive any other immunomodulator during this study. 
Only patients with PM received 20 mg methylprednisolone and 
150 mg azathioprine as a concurrent treatment. Finally, age- and 
sex-matched control blood specimens were obtained from 15 
healthy volunteers (8 women and 7 men) with a mean age of 59.4 
years (range 34–82 years).  
 Determination of MMP-2, MMP-9, TIMP-1 and TIMP2 
 Whole blood samples were obtained after written informed 
consent by venous puncture before IVIG therapy, on day 8, and 
60 days after starting a 5-day administration of a total of 120–
160 g high-dose IVIG (2 mg/kg b.w.). Samples were immediate-
ly stored on ice, directly centrifuged and stored frozen at 
–80  °  C. 
 Commercially available ELISA kits were used to determine the 
concentration of MMP-2, MMP-9, TIMP-1 and TIMP-2 in EDTA 
serum (Chemicon, Temecula, Calif., USA). According to the 
manufacturer’s directions, the MMP-9 and MMP-2 ELISA mea-
sure the pro-form of MMP-9 and the pro-MMP-2/TIMP-1 com-
plex or the pro-form of MMP-2 and pro-MMP-2/TIMP-2 com-
plex, respectively. The TIMP-1 ELISA detects TIMP-1 and the 
complex of TIMP-1 with the pro- and active forms of MMPs. As-
says were performed following the manufacturer’s instructions. 
Samples of each individual patient were analyzed on one plate. All 
standards and samples were assayed in duplicate. In addition, 
sample vials of IVIG were tested for MMP and TIMP contamina-
tion. 
 Statistical Analysis 
 The statistical analysis was performed using the paired t-test. 
Wilks’ multivariate test of significance was performed to compare 
MMP-2, MMP-9, TIMP-1 and TIMP-2 levels at different times. 
The Mann-Whitney test was used to compare the results obtained 
in patients and control subjects. p  ! 0.05 was considered as statis-
tically significant. 
 Results 
 Clinical Course. The course of disease in all patients 
was relapsing and refractory to other immunomodula-
tors. We could not detect any containment of MMPs or 
TIMPS in the IVIG vials administered. A slight statisti-
cally non-significant clinical improvement was evident 
between days 8 and 30 after IVIG therapy in almost all 
chronically ill patients ( table 1 ). Thereafter, a decline in 
clinical condition was obvious in all patients and a re-
peated course of IVIG treatment was administered. 
 Baseline Results. Before therapy, baseline MMP-2 se-
rum levels were significantly lower and MMP-9 serum 
levels significantly elevated in all patients compared to 
healthy controls with the exception of PM ( fig. 1 ). 
 Sporadic Inclusion Body Myositis. In sIBM patients, a 
significant increase of MMP-2 and TIMP-1 was found on 
day 8, but after 60 days only the MMP-2 serum levels were 
still significantly elevated compared to pretreatment lev-
els. The elevated levels of MMP-2 on days 8 and 60 reached 
values comparable to untreated age-matched controls.  
 Polymyositis. In PM patients on days 8 and 60, only 
elevated TIMP-1 levels were found. An up to 50% in-
crease compared to controls was found. 
 Multifocal Motor Neuropathy. In MMN patients, a sig-
nificant MMP-2 serum level elevation was found on days 
8 and 60. The day 60 MMP-2 levels almost approached 
control levels. In addition, on day 8 a significant TIMP-2 
elevation was found followed by a decrease on day 60. 
 Chronic Inflammatory Neuropathy. The preliminary 
results in 3 CIDP patients showed differences of MMP-2 
serum levels only on day 60 ( fig. 1 ). 
 MMP to TIMP Ratio. The change in the MMP-9 to 
TIMP-1 ratio paralleled the course of MMP-9 showing a 
decrease on day 8 and an increase on day 60 ( table 2 ). 
During the whole study period, the MMP-9 to TIMP-1 
ratio for all diseases was higher than values of the control 
group with the exception of PM and MMN on day 8. The 
differences were not statistically significant either on day 
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8 (p  ! 0.065) or day 60 (p  ! 0.086) ( table 2 ). In addition, 
before and 8 days after treatment the MMP-2 to TIMP-2 
ratio was statistically lower compared to controls (p  ! 
0.017 and p  ! 0.018–0.024). On day 60, a non-significant 
increase of the MMP-2 to TIMP-2 ratio approaching con-
trol levels was found ( table 2 ). 
 Discussion 
 MMPs are proteolytic enzymes involved in degrading 
and remodeling the ECM in response to e.g. inflamma-
tory autoimmune processes like PM or CIDP. This study 
is one of the first attempts to monitor peripheral blood 
MMP and TIMP levels in inflammatory myopathies and 
immune-mediated neuropathies before, during and after 
60 days of high-dose IVIG therapy.  
 In contrast to a previous study on expression of MMPs 
and TIMPs in inflammatory myopathies, we were able to 
measure MMP-2, MMP-9 and TIMP-1 and TIMP-2 in 
sera of controls and all patients  [6] . Although in the prior 
study MMPs and TIMPs were present in human muscle 
tissue, in sera of the same patients neither MMP-9 nor 
TIMP-1 activity was found using gelatin zymography 
and ELISA analysis  [6] . This result is in obvious contrast 
to other reported studies of MMPs and TIMPs in multi-
ple sclerosis and Guillian-Barré syndrome patients  [11–
13] . Consequently, we suppose an ELISA assay-depen-
dent effect for this inconsistency. 
 Regarding IVIG effects on MMP expression, so far 
only one study has reported dose-dependent inhibition of 
IVIG on MMP-9 protein activity and its mRNA expres-
sion in human monocytic cells  [14] . F(ab) 2 , but not Fc 
fragments, led to suppressed MMP-9 activity. Neverthe-
sIBM PM MMN CIDP
mean SE mean SE mean SE mean SE
Patients, n 15 4 11 3
MCR sum score (max. 130)*
Day 0 109.5 7.5 101.5 5.5 118.5 7.5 113.0 4.5
Day 8 110.0 5.0 102.5 6.0 120 4.5 115 5.0
Day 30 111.5 5.5 105.5 4.5 123.0 6.0 119.5 7.0
Day 60 108.4 6.5 100.3 3.5 114.1 5.5 110.3 2.5
Angelini score (max. 12)*
Day 0 8.6 0.4 8.0 0.2 9.5 0.3 9.7 0.5
Day 8 8.6 0.2 8.2 0.2 9.5 0.1 10 0.3
Day 30 9.0 0.5 8.4 0.1 9.5 0.5 10.2 0.4
Day 60 8.1 0.4 7.8 0.3 9.0 0.5 9.7 0.4
Neuromuscular symptoms score (max. 35)*
Day 0 28.7 0.2 27.5 0.4 33.7 0.7 33.3 0.1
Day 8 29.0 0.7 27.5 0.9 33.0 0.4 33.3 0.8
Day 30 31.5 0.9 28.7 0.6 34.5 0.6 33.9 0.6
Day 60 30.1 0.7 28.0 0.4 33.6 0.7 33.7 0.5
* All differences are statistically non-significant (p < 0.5).
Table 1. Prospective clinical follow-up 
data in IVIG-treated patients with 
 neuromuscular diseases
Table 2. Ratios of MMP and TIMP serum levels in inflammatory 
neuromuscular diseases and healthy controls (mean values are 
shown)
Patients Controls
sIBM PM MMN CIDP
Samples, n 15 4 11 3 15
MMP-9/TIMP-1
Day 0 8.51 8.06 7.38 15.61 4.44
Day 8 5.73 3.84 4.04 9.18
Day 60 10.0 5.7 9.55 16.4
MMP-2/TIMP-2
Day 0 9.74 11.70 9.45 10.03 12.67
Day 8 11.63 9.55 8.49 9.93
Day 60 12.4 13.86 13.86 15.02
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less, competitive experiments demonstrated that Fc but 
not F(ab) 2  fragments reversed IVIG-induced inhibitory 
effects. Additionally, no changes in MMP-2 activity levels 
were found using gelatin zymography. The authors con-
cluded that the whole IgG molecule might be needed for 
relevant IVIG-induced MMP-9 downregulation  [14] . 
Thus, IVIG may introduce stabilization of altered ratios 
of MMPs and their TIMPs in peripheral nerves and skel-
etal muscles. 
 Our results are in accordance with these findings. 
Baseline elevated MMP-9 serum levels significantly 
dropped after IVIG treatment and may indicate tissue 
repair, while posttreatment increased MMP-2 levels indi-
cate relapsing tissue damage. Moreover, 60 days after 
treatment, all the immune-mediated disorders investi-
gated here showed relapsing MMP and TIMP levels and 
no long-lasting significant change in MMPs/TIMPs ra-
tios was found. This parallels the well-known clinical im-
provement and relapse of these diseases under IVIG ther-
apy. Thus, even high-dose IVIG seems to modulate the 
inflammatory ECM attack for a short period only. 
 In summary, ELISA quantification of MMPs and their 
inhibitors in serum appears to be sensitive to provide a 
method for monitoring enzyme levels longitudinally un-
der IVIG therapy. At this stage of investigation we cannot 
completely exclude that our observations may be solely 
due to a non-specific effect of immunoglobulins. Further 
studies may provide evidence on whether MMP/TIMP 
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 Fig. 1. Mean, standard deviation and minimal and maximal  values of MMP-2, MMP-9, TIMP-1 and TIMP-2 
serum levels, presented for all diseases and controls. Mean values are indicated by cross-bars. The box-blot rep-
resents standard deviations, and vertical lines mark minimal and maximal values of serum levels.  * p  1 0.5 is 
expressed on top of the min-max lines. All values are given in ng/ml. Co = Controls; Pre = before IVIG therapy, 
D8 = day 8, D60 = day 60. 
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serum level changes are a biomarker for clinical response 
to IVIG and related immunosuppressive treatment that 
may lead to a prolonged anti-inflammatory ECM remod-
eling in distinct diseases. 
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